摘要
目的探讨应用促红细胞生成素治疗老年肺癌贫血患者的临床效果及其安全性。方法选择2009年12月～2010年12月间入本院治疗的28例老年肺癌合并贫血患者,对其采用促红细胞生成素注射治疗,每次10000单位,皮下注射,每周2次,连续治疗8周,检测患者治疗前后血红蛋白(Hb)、红细胞比容(HCT)、网织红细胞百分数(RET,%)的变化,同时观察药物的不良反应。结果 28例患者治疗前血红蛋白为(80.4±11.01)g.L-1,红细胞比容为(23.1±3.0)%,网织红细胞百分数为(1.02±0.07)%;而治疗后血红蛋白为(110.2±8.1)g.L-1,红细胞比容为(36.9±3.9)%,网织红细胞百分数为(1.84±0.09)%,均较治疗前显著升高(P<0.05)。治疗的总有效率达78.57%,治疗过程中所有患者均无皮疹、头痛、发热等不良反应发生,9例患者血压轻度增高,均为治疗前伴有高血压症状,但是通过增加降压药物用量,血压均得到了有效控制。结论促红细胞生成素治疗老年肺癌合并贫血疗效显著,安全性好,值得推广使用。
Objective To investigate the clinical effect oferythropoietin （EPO） on anemia in elderly lung cancer. Methods 28 cases of elderly lung cancer with aneufia admitted in our hospital from December 2009 to December 2010 were randomly selected and treated with EPO injection therapy, 10 000 units once, subcutaneous injection, 2 times per week for 8 consecutive weeks. The levels of hemoglobin （Hb）, hematocrit （HCT）, reticulocyte cell percentages （RET, % ） and adverse reactions were observed and compared before and after treatment. Results Before treatement, the level of Hb was （80.4 ± 11.01） g· L^-1, HCT was （23.1± 3.0） %,, RET was （1.02 4± 0.07） %; while after treatment, he level of Hb was （110.2 ± 8.1） g·L^-1, HCT was （36.9 ±3.9） %, RET was （1.84 ± 0.09） %, which were all significantly higher than before treatment （P〈0.01）. The total effective rate was 78.57%. During the treatment period, no adverse effect such as rash, headache and fever had been observed, blood pressure slightly raised in 9 cases, which all had symptoms of hypertension before treatment and were effectively controlled through increasing the doses of hypo tensors. Conelusion Erythropoietin was effective and safe to anemia in elderly hmg cancer, which was worth being popularized in clinic.
出处
《肿瘤药学》
CAS
2012年第5期370-372,共3页
Anti-Tumor Pharmacy
关键词
红细胞生成素
贫血
老年
肺癌
临床疗效
Erythropoietin
Anemia
Senile
Lung cancer
Clinical efficacy
